New Zealand markets close in 1 hour 53 minutes
  • NZX 50

    12,053.61
    -132.09 (-1.08%)
     
  • NZD/USD

    0.6627
    -0.0031 (-0.46%)
     
  • NZD/EUR

    0.5898
    -0.0018 (-0.30%)
     
  • ALL ORDS

    7,088.50
    -159.60 (-2.20%)
     
  • ASX 200

    6,809.40
    -152.20 (-2.19%)
     
  • OIL

    87.04
    -0.31 (-0.35%)
     
  • GOLD

    1,815.60
    -14.10 (-0.77%)
     
  • NASDAQ

    14,172.76
    +23.66 (+0.17%)
     
  • FTSE

    7,469.78
    +98.32 (+1.33%)
     
  • Dow Jones

    34,168.09
    -129.61 (-0.38%)
     
  • DAX

    15,459.39
    +335.49 (+2.22%)
     
  • Hang Seng

    23,931.30
    -358.60 (-1.48%)
     
  • NIKKEI 225

    26,459.05
    -552.28 (-2.04%)
     
  • NZD/JPY

    75.9050
    -0.3540 (-0.46%)
     

ClaroNav Receives Health Canada Approval for Navient Image Guided Navigation System

·2-min read

TORONTO, December 03, 2021--(BUSINESS WIRE)--ClaroNav, a leader in surgical navigation systems with a strong track record of growth and innovation, is pleased to announce that its CKI subsidiary has received Health Canada approval for its Navient ENT and Navient Cranial as Class III medical devices. Previously both devices had been approved as Class II devices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211203005516/en/

Navient Cranial Model (Photo: Business Wire)

Navient, a computer-assisted surgical navigation system, is like a GPS for the surgeon to navigate inside the patient skull. It provides three-dimensional visualization and assists surgeons with finding their ways inside the patient sinuses and avoid critical structures such as the optic nerve and brain, while safely navigating their way to the diseased area.

"This updated clearance is critical for Navient systems that are used for critical life enhancing surgeries," says Ahmad Kolahi, CEO of CKI. "Regulatory agencies worldwide continue to focus on improving patient safety and at ClaroNav, we always strive for maximum compliance. With this additional clearance, Navient is now cleared in over 20 countries supporting our global network of distributors."

Navient Cranial is intended for trans-cranial procedures. Brain tumor is an abnormal growth of cells within the brain. Globally over 2M brain mass removal is done annually. Surgical navigation system is a standard of care for cranial procedure and enables minimally invasive surgery which improves surgical accuracy, reduces tissue damage and recovery time.

Navient ENT is intended for trans-nasal surgeries. Sinusitis is inflammation of the sinuses, which are air-filled cavities in the skull. Sinusitis is one of the most prevalent of human diseases, about 29 million Americans are affected by the chronic form of the rhinosinusitis disease with annual direct cost of over 4 billion dollars. Approximately 500,000 of these patients undergo an endoscopic sinus surgery procedure. The goal of the surgery is to restore ventilation and drainage while preserving mucosa.

Additional information: https://www.claronav.com/

About ClaroNav
ClaroNav is a medical device hardware and software company focused on surgical navigation headquartered in Toronto, Canada. ClaroNav consolidates its technology and diversify its products across surgical specialties, geography, and distributions. Navient is represented worldwide by authorized distributors. ClaroNav is dedicated to innovation and developing state-of-the-art image guided navigation systems for surgeons.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005516/en/

Contacts

ClaroNav Inc.
Ahmad Kolahi
+1 (647) 951 1525
www.claronav.com
info@claronav.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting